FP-CIT SPECT in clinically inconclusive Parkinsonian syndrome during amiodarone treatment: A study with follow-up

Nuclear Medicine Communications

Volumn 31, Issue 6, 2010, Pages 583-589

  Hambÿe, Anne Sophie ^a   Vervaet, Ann ^b   Dethy, Sophie ^a  

^a Centre Hospitalier Universitaire de Tivoli   (Belgium)

^b General Central Hospital   (Belgium)

Author keywords

Amiodarone; Drug induced Parkinsonism; Idiopathic Parkinson's disease; Iodine 123 FP CIT SPECT

Indexed keywords

AMIODARONE; IODINE 123; N OMEGA FLUOROPROPYL 2BETA CARBOMETHYL 3BETA (4 IODO PHENYL)NORTROPANE I 123; UNCLASSIFIED DRUG;

AGED; ARTICLE; CLINICAL ARTICLE; FEMALE; HUMAN; IMAGE ANALYSIS; MALE; NEUROLOGIC EXAMINATION; PARKINSON DISEASE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREMOR;

AGED; AMIODARONE; DIAGNOSIS, DIFFERENTIAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; PARKINSON DISEASE; PARKINSONIAN DISORDERS; RETROSPECTIVE STUDIES; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TROPANES;

EID: 77951734309     PISSN: 01433636     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNM.0b013e328338456e     Document Type: Article

References (23)

1. Wilson JS, Prodid PJ. Side effects from amiodarone. Am Heart J 1991; 121:158-171.
2. Hilleman D, Miller MA, Parker R, Doering P, Pieper JA. Optimal management of amiodarone therapy: efficacy and side effects. Pharmacotherapy 1998; 18:138S-145S.
3. Palakurthy PR, Iyer V, Meckler RJ. Unusual neurotoxicity associated with amiodarone therapy. Arch Intern Med 1987; 147:881-884.
4. Charness ME, Morady F, Scheinman MM. Frequent neurological toxicity associated with amiodarone therapy. Neurology 1984; 34:669-671.
5. Werner EG, Olanow CW. Parkinsonism and amiodarone therapy. Ann Neurol 1989; 25:630-632.
6. Malaterre HR, Renou C, Kallee K, Gauthier A. Akinesia and amiodarone therapy. Int J Cardiol 1997; 59:107-108.
7. Booij J, Andringa G, Rijks LJ, Vermeulen RJ, De Bruin K, Boer GJ, et al. [123I]FP-CIT binds to the dopamine transporter as assessed by biodistribution studies in rats and SPECT studies in MPTP-lesioned monkeys. Synapse 1997; 27:183-190.
8. Vlaar AM, de Nijs T, Kessels AG, Vreeling FW, Winogrodzka A, Mess WH, et al. Diagnostic value of 123I-ioflupane and 123I-iodobenzamide SPECT scans in 248 patients with parkinsonian syndromes. Eur Neurol 2008; 59:258-266.
9. Marshall V, Grosset D. Role of dopamine transporter imaging in routine clinical practice. Mov Disord 2003; 18:1415-1423.
10. Benamer TS, Patterson J, Grosset DG, Booij J, de Bruin K, van Royen E, et al. Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group. Mov Disord 2000; 15:503-510.
11. Benamer HT, Patterson J,Wyper DJ, Hadley DM, Macphee GJ, Grosset DG. Correlation of Parkinson's disease severity and duration with 123I-FP-CIT SPECT striatal uptake. Mov Disord 2000; 15:692-698.
12. Montastruc JL, Llau ME, Rascol O, Senard JM. Drug-induced parkinsonism: a review. Fundam Clin Pharmacol 1994; 8:293-306.
13. Friedman JH, Lannon MC. Clozapine in the treatment of psychosis in Parkinson's disease. Neurology 1989; 39:1219-1221.
14. Booij J, Speelman JD, Horstink MW, Wolters EC. The clinical benefit of imaging striatal dopamine transporters with [123I]FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism. Eur J Nucl Med 2001; 28:266-272.
15. Lorberboym M, Treves TA, Melamed E, Lampl Y, Hellmann M, Djaldetti R. [123I]-FP/CIT SPECT imaging for distinguishing drug-induced parkinsonism from Parkinson's disease. Mov Disord 2006; 21:510-514.
16. Marshall VL, Patterson J, Hadley DM, Grosset KA, Grosset DG. Two-year follow-up in 150 consecutive patients with normal dopamine transpoter imaging. Nucl Med Commun 2006; 27:933-937.
17. Marshall VL, Reininger CB, Marquardt M, Patterson J, Hadley DM, Oertel WH, et al. Parkinson's disease is overdiagnosed clinically at baseline in diagnostically uncertain cases: a 3-year European multicenter study with repeat [123I]FP-CIT SPECT. Mov Disord 2009; 24:500-508.
18. Piccotti JR, LaGattuta MS, Knight SA, Gonzales AJ, Bleavins MR. Induction of apoptosis by cationic amphiphilic drugs amiodarone and imipramine. Drug Chem Toxicol 2005; 28:117-133.
19. Kodavanti PR, Pentyala SN, Yallapragada PR, Desaiah D. Amiodarone and desethylamiodarone increase intrasynaptosomal free calcium through receptor mediated channel. Naunyn Schmiedebergs Arch Pharmacol 1992; 345:213-221.
20. Schapira AH. Mitochondria in the aetiology and pathogenesis of Parkinson's disease. Lancet Neurol 2008; 7:97-109.
21. Vereckei A, Blazovics A, Gyorgy I, Feher E, Toth M, Szenasi G, et al. The role of free radicals in the pathogenesis of amiodarone toxicity. J Cardiovasc Electrophysiol 1993; 4:161-177.
22. Matsui A, Matsuo H, Takanaga H, Sasaki S, Maeda M, Sawada Y. Prediction of catalepsies induced by amiodarone and procaine: similarity in conformation of diethylaminoethyl side chain. JPET 1998; 287:725-732.
23. Dotti MT, Federico A. Amiodarone induced parkinsonism: a case report and pathogenetic discussion. Mov Disord 1995; 10:233-234.